RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Remdesivir FDA Approved for Hospitalized COVID-19

Save

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Clinical Trial Boom or Bust in Severe COVID-19

Save

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.

Remdesivir

TNF Inhibitors or non-TNF Biologics - First Best Choice?

Save

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar

FDA Warning on NSAIDs in Pregnancy

Save

The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Save

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

Save

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.

ICI Arthritis Tied to Cancer Progression

Save

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.

Tofacitinib and Thromboembolic Risk

Save

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m

Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity

Save

A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA)  and that risk is linked to RA disease activity. 

Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients

Save

The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Save

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Biologics Beneficial in Eosinophilic Vasculitis

Save

Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.